Moving from autologous to allogeneic ACT paradigms

We have come so far in a relatively short time with Adoptive Cellular Transfer (ACT).

Novartis ups 2019 guidance after strong Q2

Novartis has revised its guidance for 2019 upwards after a strong set of Q2 figures, with its psoriasis drug Cosentyx being the star performer.

NICE changes its mind on Novartis’ Kisqali for breast cancer

FDA accelerates review of Novartis' sickle cell drug

The FDA has accelerated its review of Novartis’ sickle cell drug crizanlizumab after the company filed phase 2 results showing its effectiveness as a treatment for life threatening and pain

Novartis trims again with $390m drugs sale to Recordati

Novartis and Amgen axe BACE drug for Alzheimer's

Another Alzheimer’s disease drug has been axed after Novartis, Amgen and the Banner Alzheimer’s Institute decided to end two pivotal studies involving a medicine targeting BACE.